Sep 23, 2019
Halozyme To Participate In 2019 Cantor Global Healthcare Conference
Jul 23, 2019
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
Mar 04, 2019
Halozyme To Participate In Upcoming Investor Conferences
Dec 26, 2018
Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
Oct 30, 2018
Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties
Oct 22, 2018
Halozyme Provides Summary Results Of Data For PEGPH20 Combination Treatments Presented At ESMO 2018 Congress
Oct 04, 2018
Halozyme Publication In The Journal Clinical Cancer Research Highlights New Nonclinical Data Supporting Multiple Effects Of PEGPH20 On The Tumor Microenvironment
Sep 20, 2018
Halozyme Therapeutics To Participate In Upcoming Investor Conference
Aug 22, 2018
Halozyme Therapeutics To Participate In Upcoming Investor Conferences
Jun 11, 2018
Halozyme President And Chief Executive Officer, Dr. Helen Torley Named EY Entrepreneur Of The Year 2018 San Diego
May 29, 2018
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
Feb 27, 2018
Halozyme Therapeutics To Present At Upcoming Healthcare Conference
Jan 09, 2018
Halozyme Projects 25 To 30 Percent ENHANZE Royalty Growth In 2018
Dec 27, 2017
Halozyme Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference
Nov 15, 2017
Halozyme Therapeutics To Participate In Upcoming Healthcare Conferences
Nov 07, 2017
Halozyme Reports Third Quarter 2017 Results
Sep 14, 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Aug 25, 2017
Halozyme Therapeutics To Present At Upcoming Healthcare Conferences
Aug 04, 2017
Halozyme Therapeutics To Present At Upcoming Healthcare Conference